Nasdaq Mandates Delisting for CASI Pharmaceuticals Effective Wednesday

Rockville, Wednesday, 25 February 2026.
CASI Pharmaceuticals (NASDAQ:CASI) has reached a critical regulatory impasse, receiving a formal delisting determination from the Nasdaq Hearings Panel. Effective February 26, 2026, trading of the company’s securities will be suspended as it transitions to the Over-the-Counter (OTC) market. This decision stems from a failure to meet continued listing standards, a struggle reflected in the stock’s 67% decline over the past six months to near-historic lows. Despite this financial setback and a market capitalization shrinking to $16.4 million, management asserts that operations—specifically the clinical trials for its lead candidate CID-103—will remain unaffected. This development presents a stark dichotomy for investors: a company advancing potentially best-in-class transplant therapeutics while simultaneously losing its footing on the premier public exchange.